PTGS2 and Behcet disease: A few clinical trials have targeted the immune system in BD subjects through administering treatment with adjunctive inflammatory modulation via the cyclooxygenase-2 (COX-2) inhibitor, celecoxib (CBX), with promising findings of accelerated treatment response due to the constitutional expression of COX-2 in the brain [15,16].